+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Prostate Cancer Therapeutics Market: Global Industry Perspective, Comprehensive Analysis and Forecast, 2017 - 2024

  • ID: 4853093
  • Report
  • September 2018
  • Region: Global
  • 130 pages
  • Zion Market Research
1 of 2

Enquire about COVID-19 updates for this product.

Enquire Now

The report covers forecast and analysis for the prostate cancer therapeutics market on a global and regional level. The study provides historic data of 2017 along with a forecast from 2018 to 2024 based on revenue (USD Million). The study includes drivers and restraints for the prostate cancer therapeutics market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the prostate cancer therapeutics market on a global level.

In order to give the users of this report a comprehensive view of the prostate cancer therapeutics market, we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein the product type and distribution channel are benchmarked based on their market size, growth rate, and general attractiveness.

The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new technology launch, agreements, partnerships, collaborations & joint ventures, research& development, technology and regional expansion of major participants involved in the market on the global and regional basis. Moreover, the study covers price trend analysis, the product portfolio of various companies according to the region.

The study provides a decisive view of the prostate cancer therapeutics market by segmenting the market based on product type, distribution channel, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2018 to 2024. Based on product type, the prostate cancer therapeutics market is segmented into hormonal therapy, chemotherapy, targeted therapy, and immunotherapy. The hormone therapy is further segmented as luteinizing hormone-releasing hormone (LHRH) analogs, luteinizing hormone-releasing hormone (LHRH) antagonists, and anti-androgens. Based on chemotherapy, the prostate cancer market is segregated as Jevtana, Mitoxantrone, Taxotere, Estramustine, and others agents. Based on the distribution channel, the market is segmented as a hospital pharmacy, retail pharmacy, and online pharmacy. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America and Middle East & Africa with its further divided into major countries including the U.S., Rest of North America, U.K., Germany, France, Italy, Spain, Rest of Europe, China, Japan, India, Southeast Asia, Rest of Asia Pacific, Brazil, Rest of Latin America, GCC Countries, South Africa and Rest of Middle East and Africa. This segmentation includes demand for prostate cancer therapeutics market based on individual product type and distribution channel in all the regions and countries.

The report also includes detailed profiles of end players such as are Amgen, Inc., Pfizer, Inc., Johnson & Johnson, AbbVie, Inc., AstraZeneca, Bayer AG, Sanofi, Ipsen Group, Dendreon Corporation, and Endo Pharmaceuticals, Inc.

This report segments the global Prostate cancer therapeutics market as follows:

Global Prostate Cancer Therapeutics Market: Product Type Segment Analysis

  • Hormonal Therapy
  • Luteinizing Hormone-releasing Hormone (LHRH) Analogs
  • Zoladex 
  • Lupron 
  • Eligard 
  • Decapeptyl 
  • Others 
  • Luteinizing Hormone-releasing Hormone (LHRH) Antagonists
  • Anti-androgens
  • Chemotherapy 
  • Jevtana
  • Mitoxantrone
  • Taxotere
  • Estramustine
  • Others 
  • Targeted Therapy 
  • Immunotherapy

Global Prostate Cancer Therapeutics Market: End-User Segment Analysis

  • Hospital Pharmacy Pharmacy
  • Retail Pharmacy
  • Online Pharmacy 

Global Prostate Cancer Therapeutics Market: Regional Segment Analysis

  • North America
  • The U.S.
  • Europe
  • UK
  • France
  • Germany
  • Asia Pacific
  • China
  • Japan
  • India
  • Latin America
  • Brazil
  • Middle East and Africa
Note: Product cover images may vary from those shown
2 of 2
  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  • Chapter 2. Executive Summary
    • 2.1. Global Prostate cancer therapeutics market, 2017 - 2024(USD Million)
    • 2.2. Global Prostate cancer therapeutics market: snapshot
  • Chapter 3. Prostate cancer therapeutics Market- Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Global Prostate cancer therapeutics market drivers: impact analysis
      • 3.2.2. Inventive Drugs Development
      • 3.2.3. Rising Research & Development Activities in Oncology Therapeutic Area
      • 3.2.4. Developments in Genomics & Proteomics
    • 3.3. Market Restraints
      • 3.3.1. Global Prostate cancer therapeutics market restraints: impact analysis
      • 3.3.2. Adverse Drug Reaction of Treatment
      • 3.3.3. High Cost Associated with the Treatment
      • 3.3.4. Low Success Rate in Clinical Testing for Cancer Drugs
    • 3.4. Opportunities
      • 3.4.1. Limited Players in the Market
      • 3.4.2. Increasing Older Male Population
      • 3.4.3. Increasing Pharmaceutical Expenditure by Emerging Markets
      • 3.4.4. High Unmet Needs
    • 3.5. Porter's five forces analysis
      • 3.5.1. Bargaining power of suppliers
      • 3.5.2. Bargaining power of buyers
      • 3.5.3. Threat from new entrants
      • 3.5.4. Threat from new substitutes
      • 3.5.5. Degree of competition
    • 3.6. Market Attractiveness Analysis
      • 3.6.1. Market attractiveness analysis, by product type segment
      • 3.6.2. Market attractiveness analysis, by distribution channel segment
      • 3.6.3. Market attractiveness analysis, by regional segment
  • Chapter 4. Global Prostate cancer therapeutics Market- Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global Prostate cancer therapeutics market: company market share, 2017
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New product launch
      • 4.2.3. Agreements, partnerships, collaborations and joint ventures
      • 4.2.4. Research and development and regional expansion
  • Chapter 5. Global Prostate cancer therapeutics Market- Product Type Segment Analysis
    • 5.1. Global Prostate cancer therapeutics market: product overview
      • 5.1.1. Global Prostate cancer therapeutics market revenue share, by product type, 2017 and 2024
    • 5.2. Hormonal Therapy
      • 5.2.1. Global Prostate cancer therapeutics market for Hormonal Therapy, 2017 - 2024(USD Million)
        • 5.2.1.1. Global prostate cancer therapeutics market, by Luteinizing Hormone-releasing Hormone (LHRH) Analogs
          • 5.2.1.1.1. Zoladex
          • 5.2.1.1.2. Lupron
          • 5.2.1.1.3. Eligard
          • 5.2.1.1.4. Decapeptyl
          • 5.2.1.1.5. Others
        • 5.2.1.2. Global prostate cancer therapeutics market, by Luteinizing Hormone-releasing Hormone (LHRH) Antagonists
        • 5.2.1.3. Global prostate cancer therapeutics market, by Anti-androgens
    • 5.3. Chemotherapy
      • 5.3.1. Global Prostate cancer therapeutics market for Chemotherapy, 2017 - 2024 (USD Million)
        • 5.3.1.1. Jevtana
        • 5.3.1.2. Mitoxantrone
        • 5.3.1.3. Taxotere
        • 5.3.1.4. Estramustine
        • 5.3.1.5. Others
    • 5.4. Targeted Therapy
      • 5.4.1. Global Prostate cancer therapeutics market for Targeted Therapy, 2017 - 2024 (USD Million)
    • 5.5. Immunotherapy
      • 5.5.1. Global Prostate cancer therapeutics market for Immunotherapy, 2017 - 2024 (USD Million)
  • Chapter 6. Global Prostate cancer Therapeutics Market- Distribution channel Segment Analysis
    • 6.1. Global Prostate cancer therapeutics market: Distribution channel type overview
      • 6.1.1. Global Prostate cancer therapeutics market revenue share, by Distribution channel, 2017 and 2024
    • 6.2. Hospital Pharmacy
      • 6.2.1. Global Prostate cancer therapeutics market for Hospital Pharmacy, 2017 - 2024 (USD Million)
    • 6.3. Retail Pharmacy
      • 6.3.1. Global Prostate cancer therapeutics market for Retail Pharmacy, 2017 - 2024 (USD Million)
    • 6.4. Online Pharmacy
      • 6.4.1. Global Prostate cancer therapeutics market for Online Pharmacy,2017 - 2024(USD Million)
  • Chapter 7. Global Prostate cancer therapeutics Market- Regional Segment Analysis
    • 7.1. Global Prostate cancer therapeutics market: regional overview
      • 7.1.1. Global Prostate cancer therapeutics market revenue share, by region, 2017 and 2024
    • 7.2. North America
      • 7.2.1. North America Prostate cancer therapeutics market revenue, by product type, 2017 - 2024(USD Million)
      • 7.2.2. North America Prostate cancer therapeutics market revenue, by Distribution channel, 2017 - 2024(USD Million)
      • 7.2.3. U.S.
        • 7.2.3.1. U.S. Prostate cancer therapeutics market revenue, by product type, 2017 - 2024(USD Million)
        • 7.2.3.2. U.S. Prostate cancer therapeutics market revenue, by Distribution channel, 2017 - 2024(USD Million)
      • 7.2.4. Rest of North America
        • 7.2.4.1. Rest of North America Prostate cancer therapeutics market revenue, by product type, 2017 - 2024(USD Million)
        • 7.2.4.2. Rest of North America Prostate cancer therapeutics market revenue, by Distribution channel, 2017 - 2024(USD Million)
    • 7.3. Europe
      • 7.3.1. Europe Prostate cancer therapeutics market revenue, by product type, 2017 - 2024(USD Million)
      • 7.3.2. Europe Prostate cancer therapeutics market revenue, by Distribution channel, 2017 - 2024(USD Million)
      • 7.3.3. U.K.
        • 7.3.3.1. U.K. Prostate cancer therapeutics market revenue, by product type, 2017 - 2024 (USD Million)
        • 7.3.3.2. U.K. Prostate cancer therapeutics market revenue, by Distribution channel, 2017 - 2024(USD Million)
      • 7.3.4. Germany
        • 7.3.4.1. Germany Prostate cancer therapeutics market revenue, by product type, 2017 - 2024(USD Million)
        • 7.3.4.2. Germany Prostate cancer therapeutics market revenue, by Distribution channel, 2017 - 2024(USD Million)
      • 7.3.5. France
        • 7.3.5.1. France Prostate cancer therapeutics market revenue, by product type, 2017 - 2024(USD Million)
        • 7.3.5.2. France Prostate cancer therapeutics market revenue, by Distribution channel, 2017 - 2024(USD Million)
      • 7.3.6. Italy
        • 7.3.6.1. Italy Prostate cancer therapeutics market revenue, by product type, 2017 - 2024(USD Million)
        • 7.3.6.2. Italy Prostate cancer therapeutics market revenue, by Distribution channel, 2017 - 2024(USD Million)
      • 7.3.7. Spain
        • 7.3.7.1. Spain Prostate cancer therapeutics market revenue, by product type, 2017 - 2024(USD Million)
        • 7.3.7.2. Spain Prostate cancer therapeutics market revenue, by Distribution channel, 2017 - 2024(USD Million)
      • 7.3.8. Rest of Europe
        • 7.3.8.1. Rest of Europe Prostate cancer therapeutics market revenue, by product type, 2017 - 2024(USD Million)
        • 7.3.8.2. Rest of Europe Prostate cancer therapeutics market revenue, by Distribution channel, 2017 - 2024(USD Million)
    • 7.4. Asia Pacific
      • 7.4.1. Asia Pacific Prostate cancer therapeutics market revenue, by product type, 2017 - 2024 (USD Million)
      • 7.4.2. Asia Pacific Prostate cancer therapeutics market revenue, by Distribution channel, 2017 - 2024(USD Million)
      • 7.4.3. China
        • 7.4.3.1. China Prostate cancer therapeutics market revenue, by product type, 2017 - 2024(USD Million)
        • 7.4.3.2. China Prostate cancer therapeutics market revenue, by Distribution channel, 2017 - 2024(USD Million)
      • 7.4.4. Japan
        • 7.4.4.1. Japan Prostate cancer therapeutics market revenue, by product type, 2017 - 2024(USD Million)
        • 7.4.4.2. Japan Prostate cancer therapeutics market revenue, by Distribution channel, 2017 - 2024(USD Million)
      • 7.4.5. India
        • 7.4.5.1. India Prostate cancer therapeutics market revenue, by product type, 2017 - 2024(USD Million)
        • 7.4.5.2. India Prostate cancer therapeutics market revenue, by Distribution channel, 2017 - 2024(USD Million)
      • 7.4.6. Southeast Asia
        • 7.4.6.1. Southeast Asia Prostate cancer therapeutics market revenue, by product type, 2017 - 2024(USD Million)
        • 7.4.6.2. Southeast Asia Prostate cancer therapeutics market revenue, by Distribution channel, 2017 - 2024(USD Million)
      • 7.4.7. Rest of Asia Pacific
        • 7.4.7.1. Rest of Asia Pacific Prostate cancer therapeutics market revenue, by product type, 2017 - 2024(USD Million)
        • 7.4.7.2. Rest of Asia Pacific Prostate cancer therapeutics market revenue, by Distribution channel, 2017 - 2024(USD Million)
    • 7.5. Latin America
      • 7.5.1. Latin America Prostate cancer therapeutics market revenue, by product type, 2017 - 2024(USD Million)
      • 7.5.2. Latin America Prostate cancer therapeutics market revenue, by distribution channel, 2017 - 2024(USD Million)
      • 7.5.3. Brazil
        • 7.5.3.1. Brazil Prostate cancer therapeutics market revenue, by product type, 2017 - 2024(USD Million)
        • 7.5.3.2. Brazil Prostate cancer therapeutics market revenue, by Distribution channel, 2017 - 2024(USD Million)
      • 7.5.4. Rest of Latin America
        • 7.5.4.1. Rest of Latin America Prostate cancer therapeutics market revenue, by product type, 2017 - 2024(USD Million)
        • 7.5.4.2. Rest of Latin America Prostate cancer therapeutics market revenue, by Distribution channel, 2017 - 2024(USD Million)
    • 7.6. Middle East and Africa
      • 7.6.1. Middle East and Africa Prostate cancer therapeutics market revenue, by product type, 2017 - 2024(USD Million)
      • 7.6.2. Middle East and Africa Prostate cancer therapeutics market revenue, by distribution channel, 2017 - 2024(USD Million)
      • 7.6.3. GCC Countries
        • 7.6.3.1. GCC Countries Prostate cancer therapeutics market revenue, by product type, 2017 - 2024(USD Million)
        • 7.6.3.2. GCC Countries Prostate cancer therapeutics market revenue, by Distribution channel, 2017 - 2024(USD Million)
      • 7.6.4. Rest of Middle East and Africa
        • 7.6.4.1. Rest of Middle East and Africa Prostate cancer therapeutics market revenue, by product type, 2017 - 2024(USD Million)
        • 7.6.4.2. Rest of Middle East and Africa Prostate cancer therapeutics market revenue, by Distribution channel, 2017 - 2024(USD Million)
  • Chapter 8. Company Profile
    • 8.1. Amgen, Inc.
      • 8.1.1. Overview
      • 8.1.2. Financials
      • 8.1.3. Product portfolio
      • 8.1.4. Business strategy
      • 8.1.5. Recent developments
    • 8.2. Pfizer, Inc.
      • 8.2.1. Overview
      • 8.2.2. Financials
      • 8.2.3. Product portfolio
      • 8.2.4. Business strategy
      • 8.2.5. Recent developments
    • 8.3. Johnson & Johnson
      • 8.3.1. Overview
      • 8.3.2. Financials
      • 8.3.3. Product portfolio
      • 8.3.4. Business strategy
      • 8.3.5. Recent developments
    • 8.4. AbbVie, Inc.
      • 8.4.1. Overview
      • 8.4.2. Financials
      • 8.4.3. Product portfolio
      • 8.4.4. Business strategy
      • 8.4.5. Recent developments
    • 8.5. AstraZeneca
      • 8.5.1. Overview
      • 8.5.2. Financials
      • 8.5.3. Product portfolio
      • 8.5.4. Business strategy
      • 8.5.5. Recent developments
    • 8.6. Bayer AG
      • 8.6.1. Overview
      • 8.6.2. Financials
      • 8.6.3. Product portfolio
      • 8.6.4. Business strategy
      • 8.6.5. Recent developments
    • 8.7. Sanofi
      • 8.7.1. Overview
      • 8.7.2. Financials
      • 8.7.3. Product portfolio
      • 8.7.4. Business strategy
      • 8.7.5. Recent developments
    • 8.8. Ipsen Group
      • 8.8.1. Overview
      • 8.8.2. Financials
      • 8.8.3. Product portfolio
      • 8.8.4. Business strategy
      • 8.8.5. Recent developments
    • 8.9. Dendreon Corporation
      • 8.9.1. Overview
      • 8.9.2. Financials
      • 8.9.3. Product portfolio
      • 8.9.4. Business strategy
      • 8.9.5. Recent developments
    • 8.10. Endo Pharmaceuticals, Inc.
      • 8.10.1. Overview
      • 8.10.2. Financials
      • 8.10.3. Product portfolio
      • 8.10.4. Business strategy
      • 8.10.5. Recent developments
Note: Product cover images may vary from those shown
Adroll
adroll